Models of high-grade serous carcinoma of tubo-ovarian origin
Oncology Reviews · 15.07.2026 · 20
DOI: 10.3389/or.2026.1849834 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Oncology Reviews, online erschienen am 15.07.2026. Verfasst von Achuth Padmanabhan und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biological Sciences, University of Maryland Baltimore County, Baltimore, MD, United States. Die Arbeit nennt 174 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS.
Abstract (Originalsprache)
Biological models aim to recapitulate the molecular and histologic characteristics, as well as the carcinogenesis of the disease of interest, to enable high-fidelity experimentation and impactful translational development. In high-grade serous carcinoma of ovarian, tubal, or peritoneal origin, there is a need to regularly re-evaluate the experimental models being employed to address research questions. This review aims to provide a resource for better understanding the applications, strengths, and limitations of the available models. This work discusses the origin and carcinogenesis of high-grade serous carcinoma and reviews normal cell-of-origin models, as understanding the cellular origin is critical to experimental efforts focused on pathogenesis, disease progression, and prevention. High-grade serous carcinoma cell lines are discussed, including essential and complementary molecular features, cell line management, and limitations. Next, the review examines advances in organoids, with a specific focus on patient-derived organoids from ascites and single-cell suspensions, organ-on-a-chip platforms, and tissue slice technologies. Finally, given the heterogeneity of epithelial ovarian cancer in general, and high-grade serous carcinoma in particular, and the evolving understanding of the importance of the tumor microenvironment, in vivo models capture organism-level complexity. In this review, we focused on high-grade serous carcinoma. In this context, we review patient-derived xenograft (PDX), syngeneic, and genetically engineered mouse models. Each has its own advantages and disadvantages, and guidance is provided on the optimal use of these in vivo approaches for the study of high-grade serous carcinoma.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Biological Sciences, University of Maryland Baltimore County, Baltimore, MD, United States.
- University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore, MD, United States.
- Peggy and Charles Stephenson Cancer Center, The University of Oklahoma Health Sciences, Oklahoma City, OK, United States.
- Department of Obstetrics and Gynecology, the University of Oklahoma Health Sciences, Oklahoma City, OK, United States.
- The Daffodil Centre, The University of Sydney, and Cancer Council NSW, Sydney, NSW, Australia.
- Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia.
Förderung
- NCI NIH HHS
Zitieren
APA
Padmanabhan, A., Dwivedi, S., Merritt, M. A., Verma, P., Buckanovich, R. J., Lang, J. D., Dimmick, H., Nephew, K. P., Drapkin, R., Brubaker, L. W., & Bitler, B. G. (2026). Models of high-grade serous carcinoma of tubo-ovarian origin. Oncology Reviews, 20. https://doi.org/10.3389/or.2026.1849834
Vancouver
Padmanabhan A, Dwivedi S, Merritt MA, Verma P, Buckanovich RJ, Lang JD, et al. Models of high-grade serous carcinoma of tubo-ovarian origin. Oncology Reviews. 2026;20. doi:10.3389/or.2026.1849834
BibTeX
@article{Padmanabhan2026,
author = {Padmanabhan, Achuth and Dwivedi, Shailendra and Merritt, Melissa A and Verma, Priyanka and Buckanovich, Ronald J and Lang, Jessica D and Dimmick, Hannah and Nephew, Kenneth P and Drapkin, Ronny and Brubaker, Lindsay W and Bitler, Benjamin G},
title = {Models of high-grade serous carcinoma of tubo-ovarian origin},
journal = {Oncology Reviews},
year = {2026},
volume = {20},
doi = {10.3389/or.2026.1849834}
}
EUVIMED